BIOMARIN PHAR. DL-,001 | 65.200 / -1.36% |
Date/Time | 04/16 / 08:04 |
Chg. / Chg.(%) | -0.900 / -1.36% |
Bid | 65.500 / 200 |
Ask | 65.680 / 200 |
Open | 65.200 |
Previous Close | 66.100 |
High | 65.200 |
Low | 65.200 |
Volume [EUR] | - |
Volume [Units] | |
Price fixings | 1 |
ISIN | US09061G1013 |
Security | BM8 |
Exchange | Stuttgart |
Type | Stock |
Other Exchanges
Exchange | Last | Volume | |
---|---|---|---|
Frankfurt | 65.6200 | ![]() |
0 |
Berlin | 65.58 | ![]() |
0 |
München | 65.60 | ![]() |
0 |
Düsseldorf | 65.38 | ![]() |
0 |
Vienna Globa.. | 65.68 | ![]() |
0 |
Lang & Schwa.. | 65.52 | ![]() |
|
Stuttgart | 65.200 | ![]() |
|
gettex | 65.820 | ![]() |
|
NASDAQ | 78.7700 | ![]() |
1,253,180 |
IEX | 78.72 | ![]() |
55,081 |
Cboe US | 78.70 | ![]() |
42,020 |
TradeGate | 66.440 | 1,345 | |
Xetra | 66.04 | 200 | |
Mexico | 1,555.62 | ![]() |
647 |
London Inter.. | 49.40 | 491 |
News
- BioMarin sinks 32% as FDA delays its hemophilia treatment
08/19/2020 / 16:23 - TeleTrader - Nasdaq turns red as pharma stocks fall
04/28/2020 / 16:48 - TeleTrader - BioMarin Enrolls First Participant in Phase 3 Trial of Vosoritide for Treatment of Children with Achondroplasia
12/12/2016 / 14:29 - GlobeNewswire - NICE Recommends BioMarin's Vimizim® (elosulfase alfa) for the Treatment of Morquio A Syndrome in England
11/23/2015 / 16:59 - GlobeNewswire